tag:blogger.com,1999:blog-7857054149675424609.post6973615264418621910..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Ionis Pays to License TTR Drug Dirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-7857054149675424609.post-55166407064599272302018-03-20T15:34:55.450+01:002018-03-20T15:34:55.450+01:00Doesn't Ionis end up with 90% of the profits f...Doesn't Ionis end up with 90% of the profits from this? 75% stake in AKCA x 40% of profits + 60% of profits paid in royalties to Ionis. It also increases its stake in Akcea and their existing portfolio. The cash paid for new shares should also end up at IONS after milestones are hit. Overall, in a few years' time we'll be able to look back and see that they kept 90% of the economicAnonymousnoreply@blogger.com